Form 4: Protagonist CMO Granted Equity Awards

Protagonist Therapeutics' Chief Medical Officer, Arturo Molina, MD, was granted 25,600 restricted stock units and 32,000 stock options.

Summary

• Arturo Molina, MD, Chief Medical Officer of Protagonist Therapeutics, Inc. (PTGX), received equity awards on January 2, 2026.
• The awards include 25,600 restricted stock units (RSUs) and 32,000 stock options.
• The RSUs were granted at a price of $0 and will vest in four equal annual installments on January 15, 2027, 2028, 2029, and 2030, subject to continued service.
• The stock options have an exercise price of $87.18 and will vest in 48 equal monthly installments following January 2, 2026, with an expiration date of January 2, 2036.
• Following these transactions, Dr. Molina beneficially owns 106,780 shares of common stock and 32,000 stock options.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The filing reports a standard equity grant to a key executive, which is generally positive for aligning management incentives with shareholder interests, but it does not contain new operational or financial news to significantly alter sentiment.

Positives

• Granting of equity awards to the Chief Medical Officer aligns management's interests with shareholders, promoting long-term retention and performance.
• The use of a Rule 10b5-1(c) plan indicates a pre-planned transaction, reducing concerns about opportunistic trading.

Future Outlook

The equity awards, consisting of restricted stock units and stock options, are subject to multi-year vesting schedules, indicating a long-term incentive structure for the Chief Medical Officer, contingent on continued service to the company through the respective vesting dates in 2027, 2028, 2029, 2030, and monthly through 2030 for options.

Industry Context

This routine equity grant to a key executive is a standard practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize top talent. Such grants are common for Chief Medical Officers, whose expertise is critical for drug development and clinical trial success, aligning their long-term interests with the company's strategic goals and shareholder value creation.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with long-term company performance.
• Employees: May signal stability in executive leadership and a commitment to long-term growth.

Next Steps

• Continued service of Dr. Molina to the Issuer for the equity awards to vest.
• Future vesting of 25,600 restricted stock units in four annual installments from January 2027 to January 2030.
• Future vesting of 32,000 stock options in 48 equal monthly installments following January 2, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a key executive, which is a standard compensation practice aimed at retaining talent and aligning interests. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on existing company fundamentals and market outlook.

Keywords

Protagonist Therapeutics, PTGX, Arturo Molina, Chief Medical Officer, Form 4, SEC Filing, Equity Grant, Restricted Stock Units, Stock Options, Insider Transaction, Executive Compensation